Amendments to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) A compound of formula (I)



(I)

or a pharmaceutically acceptable salt or ester thereof, wherein

X is

1) H,
2) aryl,
3) heteroaryl or
4) a group of formula



;

wherein aryl and heteroaryl can be unsubstituted or substituted with 1 to 4 substituents selected from $\mathbf{R}^a$, as defined hereinafter;

Y is

1) H,
2) $(C_1\text{-}C_6)$alkyl,
3) $(C_3\text{-}C_7)$cycloalkyl or
4) $(C_3\text{-}C_7)$cycloalkyl-$(C_1\text{-}C_3)$alkyl;

Q is

1) aryl,
2) aryl-$(C_1\text{-}C_6)$alkyl,
3) heteroaryl or
4) heteroaryl-$(C_1\text{-}C_6)$alkyl;

wherein aryl and heteroaryl can be optionally substituted with 1 to 3 substituents selected from $\mathbf{R}^a$; and alkyl can be optionally substituted with Cy;

Cy is cycloalkyl, heterocyclyl, aryl or heteroaryl;

A is

1) $(C_1\text{-}C_6)$alkyl,

2) $(C_2\text{-}C_6)$alkenyl,
3) $(C_2\text{-}C_6)$alkynyl,
4) Cy or
5) Cy-$(C_1\text{-}C_6)$alkyl;

wherein alkyl and cycloalkyl can be optionally substituted with 1 to 2 substituents selected from $\mathbf{R^c}$, as defined hereinafter; and Cy can be optionally substituted with 1 to 3 substituents selected from $\mathbf{R^a}$;

B is

1) N or
2) C(D);

D is independently

1) H,
2) halogen,
3) $(C_1\text{-}C_6)$alkyl,
4) $(C_2\text{-}C_6)$alkenyl,
5) $(C_2\text{-}C_6)$alkynyl,
6) $-NR^bR^b$,
7) $-NO_2$ or
8) –CN;

wherein R^b is to be defined hereinafter;

E is

1) CH_2,
2) CHR^b or
3) CR^bR^c;

R1 is

1) H,
2) $(C_1\text{-}C_6)$alkyl,
3) $(C_2\text{-}C_6)$alkenyl,
4) $(C_2\text{-}C_6)$alkynyl,
5) Cy,
6) Cy-$(C_1\text{-}C_3)$alkyl,
7) $-(CH_2)_kC(O)NR^bR^b$ or
8) $(C_1\text{-}C_6)$alkoxy$(C_1\text{-}C_6)$alkyl;

wherein Cy can be unsubstituted or substituted with a group selected from $\mathbf{R^a}$ and alkyl, alkenyl, alkynyl and alkoxy can be unsubstituted or substituted with a group selected from $\mathbf{R^c}$;

R2 is

1) H,
2) $(C_1\text{-}C_9)$alkyl,
3) $(C_2\text{-}C_9)$alkenyl,
4) $(C_2\text{-}C_9)$alkynyl,

5) Cy or
6) Cy-(C_1-C_3)alkyl;

wherein Cy can be unsubstituted or substituted with a group selected from $\mathbf{R^a}$ and alkyl, alkenyl and alkynyl can be unsubstituted or substituted with a group selected from $\mathbf{R^c}$;

R3 is

1) H or
2) (C_1-C_6)alkyl;

$\mathbf{R^a}$ is independently

1) H,
2) halogen,
3) (C_1-C_6)alkyl,
4) (C_2-C_6)alkenyl,
5) (C_2-C_6)alkynyl,
6) Cy,
7) $-OR^b$,
8) $-SR^b$,
9) $-NR^bR^b$,
10) $-NR^bC(N)NR^bR^b$,
11) $-C(O)R^b$,
12) $-C(O)NR^bR^b$,
13) $-NC(O)R^b$,
14) $-SO_2NR^bR^b$,
15) $-NO_2$,
16) $-CN$,
17) $-CF_3$ or
18) amino-(C_1-C_6)alkyl;

$\mathbf{R^b}$ is independently

1) H,
2) (C_1-C_6)alkyl,
3) (C_2-C_6)alkenyl,
4) (C_2-C_6)alkynyl,
5) (C_3-C_7)cycloalkyl,
6) aryl,
7) heteroaryl,

or in the context of D, R1, R^a and R^c, $\mathbf{R^b}$ and $\mathbf{R^b}$ together with the atom to which they are attached can also form a 5 to 6 membered ring containing 1 to 2 heteroatoms selected from N, O and S;

$\mathbf{R^c}$ is independently

1) H,
2) halogen,
3) Cy,

4) –CN,
5) $-OR^b$,
6) $-SR^b$,
7) $-NR^bR^b$ or
8) $-NR^bC(N)NR^bR^b$;

k is an integer 0 or 1;

h is an integer from 0 to 4;

n is an integer 0 or 1;

m is an integer from 0 to 3;

with the proviso that the compound of formula I is not the compound



and provided that A in formula (I) is not 2-hydroxyethyl.

2. (Original) A compound according to claim 1, wherein

R2 is

1) H,
2) $(C_1\text{-}C_6)$alkyl,
3) $(C_2\text{-}C_6)$alkenyl,
4) $(C_2\text{-}C_6)$alkynyl,
5) Cy or
6) Cy-$(C_1\text{-}C_3)$alkyl;

wherein Cy can be unsubstituted or substituted with a group selected from $\mathbf{R^a}$ and alkyl, alkenyl and alkynyl can be unsubstituted or substituted with a group selected from $\mathbf{R^c}$.

3. (Currently Amended) A compound according to claim 1~~ or 2~~, wherein the compound is a compound of formula IA



IA

or a pharmaceutically acceptable salt or ester thereof,

wherein A, Q, X, Y and n are as defined in claim 1~~ or claim 2~~.

4. (Currently Amended) A compound according to claim 1~~ or 2~~, wherein the compound is a compound of formula IB



IB

or a pharmaceutically acceptable salt or ester thereof,

wherein A, D, E, X, Y, h, m and n are as defined in claim 1~~ or claim 2~~;

Q is aryl-(C_1)alkyl or heteroaryl-(C_1)alkyl, where aryl or heteroaryl are optionally substituted with 1 to 2 substituents selected from R^a.

5. (Currently Amended) A compound according to claim 1~~ or 2~~, wherein the compound is a compound of formula IC



IC

or a pharmaceutically acceptable salt or ester thereof,

wherein R2, A, D, E, Q, h, m and n are as defined in claim 1.

6. (Currently Amended) A compound according to claim 1~~ or 2~~, wherein the compound is a compound of formula ID



ID

or a pharmaceutically acceptable salt or ester thereof,

wherein A, X, D and h are as defined in claim 1 ~~or claim 2~~;

Q is aryl-(C_1)alkyl or heteroaryl-(C_1)alkyl, where aryl or heteroaryl are optionally substituted with 1 to 2 substituents selected from R^a; and

m is an integer 1 or 2.

7. (Currently Amended) A compound according to claim 1 ~~or 2~~, wherein the compound of formula I is any of the compounds no 1 to 15 or 23 to 62 as described in the Examples.

8. (Currently Amended) A compound according to claim 1 ~~or 2~~, wherein the compound of formula I is (2*R*, 2'*R*)-5-Amino-2-{3'-naphthalen-1-yl-2'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionylamino}pentanamide, (2*R*)-*N*-(4-Aminobutyl)-3-(1*H*-indol-3-yl)-2-[3-(3-phenylpropyl)-3-(2-pyridin-2-ylethyl)ureido]propionamide, (2*S*, 2'*R*)-2-{2-[3,3-Bis(2-pyridin-2-ylethyl)ureido]-3-naphthalen-1-ylpropionylamino}-4-methylsulfanylbutyramide, (2*S*, 2'*R*)-4-Methylsulfanyl-2-{3'-naphthalen-1-yl-2'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionylamino}butyramide, (2*S*, 2'*R*)-3-Methyl-2-{3'-naphthalen-1-yl-2'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]-propionylamino}butyramide, (2*R*)-*N*-cyclohexyl-3-naphthalen-1-yl-2-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionamide, (2*S*,2'*R*)-2-{3'-naphthalen-1-yl-2'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionylamino}-3-phenylpropionamide or (2S,2'R)-2-{2-[3,3-bis(2-pyridin-2-ylethyl)ureido]-3'-naphthalen-1-ylpropionylamino}-3-methylbutyramide.

9. (Currently Amended) A compound according to ~~any of the claims 1 to 8~~ claim 1 where the compound is an SSTR1 selective agonist.

10. (Currently Amended) A compound according to ~~any of the claims 1 to 8~~ claim 1 where the compound is an SSTR1 selective antagonist.

11. (Currently Amended) A pharmaceutical composition comprising as active ingredient at least one compound according to ~~any of the claims 1 to 10~~ claim 1 and at least one pharmaceutically acceptable carrier.

12. (Currently Amended) ~~Use of a compound according to any of the claims 1 to 10 for the manufacture of a pharmaceutical preparation~~ A method for the treatment and/or prevention of a disease or condition responding to targeting with a selective SSTR1 compound, comprising administering to a patient with such a disease or condition a compound according to claim 1.

13. (Currently Amended) The ~~use~~ method according to claim 12, wherein the said disease or condition is a central nervous system disease or disorder, a disease or condition benefiting from the use of anti-proliferative agents, pathological condition in the retina and/or iris-ciliary body, diabetic complication, cancer or excessive proliferation of normal or malignant tissue.

14. (Currently Amended) The ~~use~~ method according to claim 12, wherein the said disease or condition is anxiety, depression or schizophrenia.

15. (Currently Amended) The ~~use~~ method according to claim 12, wherein the said disease or condition is prostatic cancer, benign prostatic hyperplasia, pancreatic cancer, thyroid cancer, brain tumor or gastro-intestinal tumor.

16. (Currently Amended) The ~~use~~ method according to claim 12, wherein the said disease or condition is diabetic retinopathy, diabetic nephropathy or diabetic neuropathy.

17. (Currently Amended) The ~~use~~ method according to claim 12, wherein the said disease or condition is angiogenesis, vascular restenosis, smooth muscle proliferation, endothelial cell proliferation, new blood vessel sprouting or neovascularization.

18. (Currently Amended) ~~Use of a compound of according to any of the claims 1-10 in combination with a detectable label,~~ A method for targeting tissues bearing SSTR1s for tissue imaging, comprising administering a compound according to claim 1 in combination with a detectable label.

19. (Currently Amended) ~~Use of a compound of according to any of the claims 1-10 as a carrier for another~~ A method for targeting a therapeutically active compound ~~to be targeted~~ to tissues bearing SSTR1s, comprising administering said therapeutically active compound with a compound according to claim 1 as a carrier for said therapeutically active compound.